Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q3 FY21 results · Oct–Dec 2020
Dr. Lal Path Labs reported revenue from operations of ₹452.40 crore (up 38.0% from Q3 FY20) and net profit of ₹95.90 crore (up 74.7% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 452.40 | 327.90 | +38.0% | 431.90 | +4.7% |
| Other income | 13.50 | 13.80 | −2.2% | 12.90 | +4.7% |
| Total income | 465.90 | 341.70 | +36.3% | 444.80 | +4.7% |
| Profit before tax | 128.90 | 73.40 | +75.6% | 116.60 | +10.5% |
| Net profit for the period | 95.90 | 54.90 | +74.7% | 87.10 | +10.1% |
| Attributable to shareholders of the company | 94.50 | 54.10 | +74.7% | 85.30 | +10.8% |
| EPS, basic (₹) | 11.44 | 6.56 | +74.4% | 10.34 | +10.6% |
| Net margin (%) | 21.2 | 16.7 | 20.2 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 427.10 | 310.40 | +37.6% | 404.30 | +5.6% |
| Other income | 14.60 | 13.30 | +9.8% | 12.50 | +16.8% |
| Total income | 441.70 | 323.70 | +36.5% | 416.80 | +6.0% |
| Profit before tax | 124.10 | 68.60 | +80.9% | 106.80 | +16.2% |
| Net profit for the period | 92.70 | 51.10 | +81.4% | 79.90 | +16.0% |
| EPS, basic (₹) | 11.23 | 6.20 | +81.1% | 9.68 | +16.0% |
| Net margin (%) | 21.7 | 16.5 | 19.8 |
Consolidated
- Filed with BSE
- 29 Jan 2021, 18:17 IST
- Board meeting
- 29 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jan 2021, 18:17 IST
- Board meeting
- 29 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE